Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessAttribution 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/Tarih
2020Yazar
Hacıoğlu, Muhammet BekirKöstek, Osman
Karabulut, Senem
Taştekin, Didem
Sezgin Göksu, Sema
Alandağ, Celal
Akagündüz, Baran
Bilgetekin, İrem
Caner, Burcu
Şahin, Ahmet Bilgehan
Yıldız, Birol
Köse, Fatih
Kaplan, Muhammet Ali
Gülmez, Ahmet
Doğan, Ender
Güven, Deniz Can
Gürbüz, Mustafa
Ergun, Yakup
Karaağaç, Mustafa
Demiray, Atike Gökçen
Türker, Sema
Sakalar, Teoman
Özkul, Özlem
Akın Telli, Tuğba
Şahin, Süleyman
Kılıçkap, Saadettin
Bilici, Ahmet
Erdoğan, Bülent
Çiçin, İrfan
Üst veri
Tüm öğe kaydını gösterKünye
Hacıoğlu, M. B., Köstek, O., Karabulut, S., Taştekin, D., Sezgin Göksu, S., Alandağ, C. ... Çiçin, İ. (2020). Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey. Journal of B.U.ON., 25(4), 1897-1903.Özet
Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the secondor third-line setting.Methods: In this retrospective and multicenter study, advanced HCC patients not eligible for local therapies, who received a secondor third-line regorafenib therapy after progression on the first-line sorafenib or sequential therapy with chemotherapy (CT) followed by sorafenib, were included.Results: In the first-line setting, 28 (28.9%) patients received CT and 69 (71.1%) patients received sorafenib. There were 24 (24.7%) patients who were intolerant to sorafenib. Disease control rate (DCR) was 53.6% for all patients treated with regorafenib, 62.3% in patients who received regorafenib in the second-line, and 32.1% for those receiving regorafenib in the third-line (p=0.007). Median progression-free survival (PFS) and overall survival (OS) were 5.6 (range; 4.3-6.9) and 8.8 (range, 6.3-11.3) months for all patients treated with regorafenib vs. 7.1 months and 10.3 months for patients who received regorafenib in the second-line vs. 5.1 and 8.7 months for patients who received regorafenib in the third-line, respectively; however, there was no statistically significant difference (p(PFS)=0.22 and p(OS)=0.85).Conclusion: Although receiving CT as a first-line therapy in advanced HCC patients did not affect the survival rates of subsequent regorafenib therapy, it might diminish the DCR of regorafenib.
WoS Q Kategorisi
Q4Scopus Q Kategorisi
Q3Kaynak
Journal of B.U.ON.Cilt
25Sayı
4Koleksiyonlar
- Makale Koleksiyonu [3676]
- PubMed İndeksli Yayınlar Koleksiyonu [4083]
- Scopus İndeksli Yayınlar Koleksiyonu [6360]
- WoS İndeksli Yayınlar Koleksiyonu [6476]